Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | IDH1 | O75874 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127374 | 1.00 | LRRK2 (0.42) | LRRK2IDH1PIK3CAAKT1MTOR | |
| SCHEMBL19686785 | 0.81 | PIK3CA (0.39) | LRRK2IDH1PIK3CAAKT1MTOR | |
| SCHEMBL31127115 | 0.81 | PIK3CA (0.39) | LRRK2IDH1PIK3CAAKT1MTOR | |
| SCHEMBL23275348 | 0.79 | PIK3CA (0.44) | IDH1PIK3CACCNT1IDH2CYP1A2 | |
| SCHEMBL21144157 | 0.79 | CYP1A2 (0.45) | LRRK2IDH1PIK3CACCNT1IDH2 | |
| SCHEMBL19686807 | 0.79 | RAF1 (0.54) | LRRK2IDH1PIK3CAHRH4IDH2 | |
| SCHEMBL31127217 | 0.79 | CYP1A2 (0.45) | LRRK2IDH1PIK3CACCNT1IDH2 | |
| SCHEMBL21165869 | 0.79 | OPRK1 (0.44) | — | |
| SCHEMBL21143962 | 0.78 | SMN1; SMN2 (0.45) | LRRK2HRH4MAPT | |
| SCHEMBL31127337 | 0.78 | SMN1; SMN2 (0.45) | LRRK2HRH4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | LRRK2 1193/4885IDH1 3017/4885PIK3CA 1182/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | LRRK2 1193/4885IDH1 3017/4885PIK3CA 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.